JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2017 financial results and a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 17334187.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
